Literature DB >> 22172300

Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010.

L Wiessing1, G Likatavicius, D Hedrich, B Guarita, M J van de Laar, J Vicente.   

Abstract

Data on newly diagnosed HIV infections and HIV prevalence in 2005 to 2010 suggest falling infection rates in injecting drug users (IDUs) in the European Union (EU). However, recent increases in HIV and hepatitis C virus (HCV) infection rates in IDUs suggest increasing injecting risks in some countries. The coverage of effective prevention measures has increased, but is still low in several countries. Overall the data suggest a continued risk of new outbreaks of HIV infection among IDUs.

Entities:  

Mesh:

Year:  2011        PMID: 22172300

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  24 in total

Review 1.  Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes.

Authors:  Simona Ruta; Costin Cernescu
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

Review 2.  Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals.

Authors:  Nicola Coppola; Mariantonietta Pisaturo; Rosa Zampino; Margherita Macera; Caterina Sagnelli; Evangelista Sagnelli
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

3.  Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution Therapy.

Authors:  Angelika Schìtz; Stephan Moser; Katharina Marchart; Hans Haltmayer; Michael Gschwantler
Journal:  Am J Gastroenterol       Date:  2016-06       Impact factor: 10.864

4.  Exploring Patient Characteristics and Barriers to Hepatitis C Treatment in Patients on Opioid Substitution Treatment Attending a Community Based Fibro-scanning Clinic.

Authors:  Des Crowley; Walter Cullen; Eamon Laird; John S Lambert; Tina Mc Hugh; Carol Murphy; Marie Claire Van Hout
Journal:  J Transl Int Med       Date:  2017-06-30

5.  Homelessness and Other Risk Factors for HIV Infection in the Current Outbreak Among Injection Drug Users in Athens, Greece.

Authors:  Vana Sypsa; Dimitrios Paraskevis; Meni Malliori; Georgios K Nikolopoulos; Anastasios Panopoulos; Maria Kantzanou; Antigoni Katsoulidou; Mina Psichogiou; Anastasios Fotiou; Anastasia Pharris; Marita Van De Laar; Lucas Wiessing; Don Des Jarlais; Samuel R Friedman; Angelos Hatzakis
Journal:  Am J Public Health       Date:  2015-01       Impact factor: 9.308

6.  Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy : Final results of the Austrian PegHope study.

Authors:  Michael Gschwantler; Hermann Laferl; Wolfgang Vogel; Wolfgang Korak; Stephan Moser; Harald Hofer; Bernhard Bauer; Michael Schleicher; Barbara Bognar; Martin Bischof; Rudolf Stauber; Andreas Maieron; Peter Ferenci
Journal:  Wien Klin Wochenschr       Date:  2017-09-12       Impact factor: 1.704

Review 7.  Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"?

Authors:  Drosos E Karageorgopoulos; Joanna Allen; Sanjay Bhagani
Journal:  World J Hepatol       Date:  2015-07-28

8.  Hepatitis C virus maintains infectivity for weeks after drying on inanimate surfaces at room temperature: implications for risks of transmission.

Authors:  Elijah Paintsil; Mawuena Binka; Amisha Patel; Brett D Lindenbach; Robert Heimer
Journal:  J Infect Dis       Date:  2013-11-23       Impact factor: 5.226

Review 9.  Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis.

Authors:  Georgie J MacArthur; Silvia Minozzi; Natasha Martin; Peter Vickerman; Sherry Deren; Julie Bruneau; Louisa Degenhardt; Matthew Hickman
Journal:  BMJ       Date:  2012-10-03

10.  Incidence of hepatitis C infection among prisoners by routine laboratory values during a 20-year period.

Authors:  Andrés Marco; Carlos Gallego; Joan A Caylà
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.